§ BIOTECHNOLOGY
USD · BiotechnologyKROS
KEROS THERAPEUTICS INC
USDSector · BiotechnologyBeta · 1.15
§ 01 · PRICE
Price action
1D5D1M6MYTD1YMAX
§ 03 · SIGNAL STACK · WHAT THE INPUTS SAY
13F FLOW
62 increased/new, 53 decreased/exited (13F)
AC 13F Analysis
§ 04 · FUNDAMENTALS · THE BOOKS
| P/E | 2.5 | P/B | 2.05 |
| EPS (TTM) | -3.70 |
§ 05 · WHO OWNS IT
Top institutional holders
| Fund | Shares | % port | Δ Q/Q |
|---|---|---|---|
| BlackRock | 2.4M | 0.0% | +5% |
| Nantahala Capital Management, LLC | 1.4M | 0.6% | +277% |
| VANGUARD CAPITAL MANAGEMENT LLC | 831K | n/a | n/a |
| ORBIMED ADVISORS LLC | 759K | 0.2% | −6% |
| Qube Research & Technologies Ltd | 725K | 0.0% | −8% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 706K | 0.0% | −8% |
◇ AC INTELLIGENCE
Top institutional owners for KROS as of the most recent 13F reporting period (Q1 2026 · Period ended Mar 31). Δ Q/Q reflects share-count change vs. the prior filing — positive green means adding, negative red means trimming. Cross-reference with the ownership-mix bars below to see which strategy cohort is driving the flow.
§ 06 · WHO OWNS IT · BY STRATEGY
OTHER52.5% · 96 holders
PASSIVE / INDEX17.3% · 7 holders
QUALITY / COMPOUNDER9.4% · 12 holders
DEALER / BANK9.2% · 19 holders
SYSTEMATIC / QUANT5.5% · 5 holders
TACTICAL / MACRO3.5% · 3 holders
ACTIVIST2.6% · 1 holder
INCOME / DEFENSIVE0.9% · 7 holders
◇ AC INTELLIGENCE
Ownership mix by behavioral cohort. Top bars indicate which style of capital dominates the float — passive indexing, quality compounders, dealer/bank, systematic quant, etc. Big quality-compounder share means concentrated active conviction; heavy passive share means flows are dictated by index rebalances, not fundamentals.
§ 07 · INSIDER ACTIVITY · LAST 180 DAYS
NO INSIDER FILINGS
◇ AC INTELLIGENCE
No Form 4 filings on record for KROS in the last 180 days.
§ 08 · COVERAGE · OUR RECENT NOTES
No notes mention KROS yet.